Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 4;30(11):1543–1553. doi: 10.1038/s41417-023-00658-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A–L Graphs representing individual cell impedance measurements in real time of ovarian cancer tumor samples in response to treatment with Ad5/3-E2F-d24-vIL2 virus, TIL therapy, and Ad5/3-E2F-d24-vIL2 virus in combination with TIL therapy. Control groups with the Ad5/3-E2F-d24 virus were also applied. Tumor single cell suspensions were plated (5 × 10⁴ cells/well) in duplicates in pre-coated plates with human fibronectin (5 μg/ml). After 24 h of incubation, samples were treated with day 14 expanded autologous TILs (3:1) effector to target ratio (E:T) concomitantly to 100vp/cell of Ad5/3-E2F-d24 or Ad5/3-E2F-d24-vIL2 virus. Plates were scanned every 15 min for a total of 190 h. Monotherapy groups respective to each therapy were used as controls of the therapy response. Data sets are presented as normalized cell index over the period of observation and analysed for statistical significance by unpaired T test and presented as mean +− SEM. Data is *p < 0.05, **p < 0.01.